FIGURE

Figure 3

ID

ZDB-FIG-231116-100

Publication

Cella et al., 2023 - Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms

Other Figures

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

All Figure Page

Back to All Figure Page

Figure 3

BON1 cells were treated with different doses of cabozantinib or sunitinib (µM), for the indicated times. (A) Analysis of MET phosphorylation. (B) Analysis of mTOR pathway. (C) Analysis of MCL-1 levels.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Endocr. Relat. Cancer